Bayer AG (WAR:BAY) Other Stockholders Equity: zł35,483 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BAY Bayer AG WAR:BAY
45 GF Score
Price zł216.00
GF Value zł115.76
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Other Stockholders Equity?

Bayer AG WAR:BAY -0.83% 45 Other Stockholders Equity is zł35,483 Mil as of Mar. 2026. GuruFocus rates WAR:BAY with a GF Score™ of 45/100 and a GF Value™ of zł115.76 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bayer AG's Other Stockholders Equity for the quarter that ended in Mar. 2026 was zł35,483 Mil.

Bayer AG's quarterly Other Stockholders Equity declined from Sep. 2025 (zł39,297 Mil) to Dec. 2025 (zł23,032 Mil) but then increased from Dec. 2025 (zł23,032 Mil) to Mar. 2026 (zł35,483 Mil).

Bayer AG's annual Other Stockholders Equity declined from Dec. 2023 (zł50,404 Mil) to Dec. 2024 (zł44,339 Mil) and declined from Dec. 2024 (zł44,339 Mil) to Dec. 2025 (zł23,032 Mil).

Bayer AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bayer AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Other Stockholders Equity Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52,625.72 72,518.05 50,403.50 44,339.20 23,032.16

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47,993.71 42,091.91 39,297.04 23,032.16 35,483.11
WAR:BAY
45GF Score
Bayer AG WAR:BAY
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of zł35,483 Mil mean?
Bayer AG (WAR:BAY) has a Other Stockholders Equity of zł35,483 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bayer AG and its competitors.
Is Bayer AG's Other Stockholders Equity too high?
Bayer AG's current Other Stockholders Equity is zł35,483 Mil. Overall, Bayer AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Other Stockholders Equity compare to LLY and JNJ?
Bayer AG's Other Stockholders Equity of zł35,483 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bayer AG and its competitors. Bayer AG's current Other Stockholders Equity is zł35,483 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (WAR:BAY) is currently considered Significantly Overvalued. The stock's GF Value™ is zł115.76, compared to a current price of zł216.00 — trading 86.6% above its estimated fair value. The current Other Stockholders Equity is zł35,483 Mil. Bayer AG's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bayer AG (WAR:BAY), the current Other Stockholders Equity is zł35,483 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (WAR:BAY) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of zł216.00 is trading 86.6% above its estimated GF Value™ of zł115.76. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for WAR:BAY:

  • Other Stockholders Equity: zł35,483 Mil
  • GF Value™: zł115.76 vs. price of zł216.00 (86.6% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the WAR:BAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
45GF Score

Get the complete analysis for WAR:BAY

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł216.00
Price
zł115.76
GF Value